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Abstract D-2-hydroxyglutaric aciduria (D2HGA) type II is a
rare neurometabolic disorder caused by germline gain-of-
function mutations in isocitrate dehydrogenase 2 (IDH2),
resulting in accumulation of D-2-hydroxyglutarate (D2HG).
Patients exhibit a wide spectrum of symptoms including car-
diomyopathy, epilepsy, developmental delay and limited life
span. Currently, there are no effective therapeutic interven-
tions. We generated a D2HGA type II mouse model by intro-
ducing the Idh2R140Q mutation at the native chromosomal
locus. Idh2R140Q mice displayed significantly elevated 2HG
levels and recapitulated multiple defects seen in patients. AGI-
026, a potent, selective inhibitor of the human IDH2R140Q-
mutant enzyme, suppressed 2HG production, rescued cardio-
myopathy, and provided a survival benefit in Idh2R140Q
mice; treatment withdrawal resulted in deterioration of cardiac
function. We observed differential expression of multiple
genes and metabolites that are associated with cardiomyopa-
thy, which were largely reversed by AGI-026. These findings
demonstrate the potential therapeutic benefit of an
IDH2R140Q inhibitor in patients with D2HGA type II.
Introduction
D-2-hydroxyglutaric aciduria (D2HGA) is a rare, inborn,
neurometabolic disorder with two genetically distinct
types (Kranendijk et al 2012). Type I is caused by
germline autosomal recessive, loss-of-function mutations
in the mitochondrial D-2-hydroxyglutarate dehydrogenase
gene (D2HGDH) (Kranendijk et al 2010a), impairing the
enzyme’s ability to convert D-2-hydroxyglutarate to
alpha-ketoglutarate (αKG) (Struys et al 2005). Type II
results from autosomal dominant, gain-of-function muta-
tions in the Arg140 residue of the mitochondrial isocitrate
dehydrogenase 2 gene (IDH2), predominantly the
IDH2R140Q mutation (Kranendijk et al 2010b). Somatic
mutations in IDH2 and IDH1 (cytosolic isoform) have
been found in multiple neoplasms (Mardis et al 2009;
Yan et al 2009), and confer neomorphic activity, allowing
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the mutant enzyme to catalyze the reduction of αKG to 2-
hydroxyglutarate (2HG) (Dang et al 2009; Gross et al
2010).
In D2HGA, IDH2 and D2HGDH mutations both result in
2HG accumulation, accompanied by developmental delay,
hypotonia and seizures, although there are phenotypic differ-
ences between the two types. Type II (IDH2 mutation) is as-
sociated with earlier onset, more severe developmental delay,
higher seizure frequency and reduced life expectancy than
type I (D2HGDH mutation), and ∼50 % of patients have car-
diomyopathy, which is not observed in type I (Kranendijk et al
2012). These variations appear to correlate with higher 2HG
levels in type II disease (Kranendijk et al 2012). There are
currently no effective therapeutic interventions other than sup-
portive use of anticonvulsants to control seizures.
Cancer metabolism studies demonstrated that 2HG is an
oncometabolite, promoting epigenetic aberrations via inhibi-
tion of αKG-dependent dioxygenases, including DNA and
histone demethylases, and impaired cellular differentiation
(Figueroa et al 2010; Chowdhury et al 2011; Xu et al 2011).
We have developed a series of selective, potent inhibitors of
the IDH2R140Q mutant protein, and demonstrated that inhi-
bition of 2HG production with these compounds reverses epi-
genetic re-wiring and promotes normal cellular differentiation,
with preliminary clinical data indicating clinical activity in
advanced hematologic malignancies (Wang et al 2013a;
Stein et al 2014; Kernytsky et al 2015). Due to the rarity of
D2HGA type II (Kranendijk et al 2012), and lack of an opti-
mal preclinical model system, understanding of disease path-
ophysiology is lacking. To address this knowledge gap, we
developed and characterized a knock-in (KI) mouse model of
D2HGA type II, which we used to evaluate the therapeutic
potential of the IDH2R140Q inhibitor AGI-026, which was
selected from our series due to its favorable potency, relative
selectivity, and especially its ability to penetrate the blood-
brain barrier.
Materials and methods
Mouse husbandry and breeding
Mice were bred and maintained in a barrier facility under
pathogen-free conditions (WuXi AppTec, Shanghai, China).
Mice were housed under 12/12 h light/dark cycles and given
ad libitum access to food and water. Experiments were con-
ducted in accordance with protocols approved by the
Institutional Animal Care and Use Committee. Prior to effica-
cy studies, a tolerability study was performed in which wild
type (wt) mice were administered 50 mg/kg AGI-026 for
7 days. We observed no changes in body weight, animal alert-
ness or activity, eating or general behavior, no gross pheno-
typic changes in bone marrow cells upon flow cytometry, and
no histopathological changes in liver, spleen, brain and heart.
For efficacy assessment, AGI-026 (2 or 10 mg/kg) or vehicle
(0.5 % w/v methylcellulose/0.25 % tween-80 diluted with pu-
rified water) was administered to male and female mice by
oral gavage, with initiation at 4–5 weeks old (post-weaning).
Body weight and overall health were continuously monitored.
Generation of D2HGA type II mouse model
The targeting vector was assembled as shown in
Supplementary Fig. 1a and contained a loxP-flanked STOP
(LSL) cassette in the preceding intron for conditional expres-
sion of the Idh2R140Q protein in a Cre-recombinase-
dependent manner, and genomic fragments of the Idh2 gene
including a 3.0 kb 5′ arm and 7.6 kb 3′ arm retrieved from
129S6/SvEv BAC DNA (Source BioScience, UK) via an E.
coli-based chromosome engineering system (Lee et al 2001).
The 3′ arm contained the murine Idh2 exon 4 bearing the
R140Q mutation, which was created by PCR-based mutagen-
esis. An FRT-flanked neomycin resistance cassette (Neor) and
a thymidine kinase gene served as selectable markers for ge-
nomic integration. The linearized targeting vector was
electroporated into 129S6/SvEv mouse embryonic stem (ES)
cells. Following homologous recombination in ES cells, an
expression vector of Flp-recombinase was transiently
transfected to delete the Neor cassette. Targeted ES cells were
identified by PCR and sequencing analyses and then injected
into C57BL/6J blastocysts, which were transferred to pseudo-
pregnant females to produce chimeric mice. Chimeric males
from two ES cell clones gave germline transmission of the
conditional KI IHD2 allele (IDH2LSL). The chimeric mice
were bred to C57BL/6J mice for germline transmission.
Mutant mice were crossed with CMV-Cre transgenic mice
on a C57BL/6J background to generate heterozygous
Idh2R140Qmice by deleting the STOP cassette. The presence
of systemic Idh2R140Q mutation was confirmed by PCR
analysis of tail genomic DNA using primers spanning the
position of the residual loxP site (5′- CTGTGCCACTGAGC
TACATCTCCAG-3 ′ and 5 ′- CGTTTTTACCAGGT
CCACATGGAAG -3′), generating a 150-bp PCR product in
Idh2wt mice and a 204-bp PCR product in KI mice. Mice
were also analyzed for the presence of Idh2R140Q by se-
quencing using PCR primers (5′-CCTGAGCCGAATGC
TTTTAAG-3′ and 5′- CTCACGCTCCTTACTGGAC-3′).
Idh2wt littermates of Idh2R140Q mice served as controls for
all analyses.
No formal sample size calculation was performed but suf-
ficient numbers ofmice were bred to ensure at least 20 animals
per treatment group for the AGI-026 treatment studies; suffi-
cient numbers were obtained to achieve statistical signifi-
cance. Animals were selected for inclusion based on confir-
mation of Idh2R140Q/wt genotype by PCR and sequencing,
and elevated plasma 2HG levels (see below for method); no
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other inclusion/exclusion criteria were applied. Mice were
randomized using the BRAND^ function in Microsoft Excel
and assignment to treatment groups based on their randomi-
zation number (0–0.25 to group 1, 0.25–0.50 to group 2,
0.50–0.75 to group 3, and 0.75–1 to group 4). This was a
non-blinded study. For each of the efficacy experiments, all
animals were treated simultaneously to ensure consistency in
experimental conditions and age of animals.
2HG assessment
Mice were euthanized by CO2 inhalation and blood was col-
lected by retro-orbital sampling (biweekly assessments) or
intracardiac puncture (end of study). Tissues including heart,
brain, liver, and skeletal muscle were dissected, flash frozen in
liquid nitrogen and stored at −80 °C until analysis. Bone mar-
row was flushed out from the tibia and femur in phosphate-
buffered saline without Mg2+ or Ca2+, and the viable cell
number determined by cell counting after trypan blue staining.
Total 2HG levels were assessed as a surrogate marker for
D2HG levels using liquid chromatography-tandem mass
spectrometry (LC-MS) as previously described (Dang et al
2009). Plasma 2HG levels were assessed every 2 weeks dur-
ing AGI-026 treatment.
Whole body histopathology
At necropsy, mouse tissues were trimmed and fixed in 10 %
neutral buffered formalin. Fixed tissues were processed, par-
affin-embedded, sectioned, and stained with hematoxylin and
eosin according to standard laboratory protocols.
Histopathological evaluation was conducted by a veterinary
pathologist.
Echocardiography
Mice were anesthetized with pentobarbital sodium (1 mg/kg)
and immobilized on a heating platform, ventral side up, to
maintain body temperature at 37.0 ± 0.5 °C. Heart rate and
respiratory physiology were continuously monitored during
examination. M mode echocardiographic studies for determi-
nation of cardiac left ventricular hypertrophy (left ventricular
mass and ejection fraction) were performed using a Vevo®
2100 system (VisualSonics, Toronto, Canada) with a
30 MHz transducer.
Biochemical and cellular properties of AGI-026
AGI-026 was prepared as a 10 mM stock in dimethyl sulfox-
ide (DMSO) and diluted to 50× final concentration in DMSO.
IDH2 mutant homodimer enzyme activity and IDH2wt/IDH2
mutant heterodimer enzyme activity of converting αKG to
2HG was measured in an end-point assay of NADPH
depletion. In this assay, the remaining cofactor was measured
at the end of the reaction period by the addition of a catalytic
excess of diaphorase and resazurin to generate a fluorescent
signal in proportion to the amount of NADPH remaining.
IDH2wt homodimer enzyme activity of converting isocitrate
to αKGwas measured in a continuous assay directly coupling
NADPH production to conversion of resazurin to resorufin by
diaphorase. In both cases, resorufin was measured via fluores-
cence (λex = 544 nm, λem = 590 nm).
Specifically, the IDH2R140Q homodimer enzyme was di-
luted to 0.31 μg/mL in 40 μL assay buffer (150 mM NaCl,
50 mM K2HPO4 pH 7.5, 10 mM MgCl2, 10 % glycerol,
0.05 % BSA) containing 1 μL of 50× compound dilution
ser ies , 5 μM NADPH cofactor, and 2.5 mM β -
mercaptoethanol, and the mixture incubated at 25 °C for
16 h. The reaction was then initiated with the addition of
10 μL of 8 mM αKG in assay buffer. The reactions were
run for 40 min at room temperature and terminated by the
addition of 25 μL of detection buffer (36 μg/mL diaphorase,
18 μM resazurin, in 1× assay buffer), shaken for 1 min on a
laboratory shaker, and read on a SpectraMax 384-well plate
reader as described above. The IDH2wt homodimer enzyme
was diluted to 0.1 μg/mL in 40 μL assay buffer containing
1 μL of 50× compound dilution series, 35 μM NADP+ co-
factor, and 2.5 mM β-mercaptoethanol, and the mixture incu-
bated at 25 °C for 16 h. The reaction was then initiated with
the addition of 10 μL of a substrate mix containing 0.2 mM
isocitrate, 60 μg/mL diaphorase, and 200 μM resazurin in
assay buffer. The reactions were run at 25 °C for 30 min,
stopped by the addition of 25 μL of 6 % SDS solution, and
read on a SpectraMax 384-well plate reader. The IDH2wt/
R140Q heterodimer enzyme was diluted to 0.25 μg/mL in
40μL assay buffer containing 1 μL of 50× compound dilution
series, 42.5 μM NADP+/5 μM NADPH cofactor mix, and
2.5 mM β-mercaptoethanol. This mixture was incubated at
25°C for 16 h. The reaction was then initiated with the addi-
tion of 10 μL of 6.25 mM αKG in assay buffer. The reactions
were run for 50 min at room temperature and terminated by
the addition of 25 μL of detection buffer, shaken for 1 min on
a laboratory shaker, and read on a SpectraMax 384-well plate
reader.
Cellular potency (IC50 determined using levels of the en-
zyme product 2HG in culture medium) was tested in mouse
ES Idh2R140Q cells and the U87 glioblastoma cell line ec-
topically overexpressing IDH2R140Q, as previously de-
scribed (Wang et al 2013a). Selectivity of AGI-026 was deter-
mined using a panel of dehydrogenases (Wang et al 2013a)
and an enzyme panel screen from CEREP (Poitiers, France).
2HG in culture medium was measured by LC-MS. Total 2HG
level was measured as a surrogate for D2HG.
Lymphoblast cells were obtained from three unrelated pa-
tients with 2DHGA type II and cultured as previously de-
scribed (Wickenhagen et al 2009). Cells were seeded in a
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96-well plate at 50,000 cells per well in 200 μl of complete
medium. Duplicate wells were seeded to obtain cell counts at
48 h post-culture (no compound administered), and indicated
150,000 cells per well. Cells were incubated with varying
concentrations of AGI-026 and culture medium was collected
after 48, 72, and 96 h. A 10 mM stock was made in DMSO
and diluted in culture medium, with a 10X dilution range
made from 10 μM down to 10 pM (seven concentrations by
tenfold sequential dilution). D2HG and L2HG in culture me-
dium were measured by LC-MS as described previously
(Struys et al 2004).
5hmC and 5mC assessment
Genomic DNA was extracted from approximately 25 mg of
heart tissue using the QIAamp DNA Mini Kit (Qiagen) ac-
cording to the manufacturer’s instructions. For each sample,
1 μg of DNAwas degraded into individual nucleosides using
DNA Degradase Plus™ (Zymo Research Corporation, Irvine,
CA). Individual nucleosides were measured using a high-
performance liquid chromatography-tandem mass spectrome-
try (HPLC-MS/MS) system consisting of a Dionex
UltiMate® 3000 UHPLC system (Thermo Scientific,
Sunnyvale, CA) containing a Kinetex HILIC column
(2.1 × 100 mm, 1.7 μm; Phenomenex Inc., Torrance, CA)
connected to a TSQ Vantage mass spectrometer (Thermo
Scientific). Quantification was performed using area-based
linear regression curves derived from calibration standards
containing internal standard solutions. 5mC and 5hmC levels
were calculated as a concentration percentage ratio of total
deoxycytidine species; %5mC = 5-methyl-2′-deoxycytidine/
(5-methyl-2 ′-deoxycytidine + 5-hydroxymethyl-2 ′-




Total RNA from frozen tissues was isolated using the RNeasy
Mini Kit (Qiagen, Germany) according to the manufacturer’s
instructions. RNA was tested for quality using a spectropho-
tometer, and was only accepted if the RNA Integrity Number
(RIN) was greater than 9.0. RNAwas extracted and sequenced
on a HiSeq 2000 system (Illumina Inc., San Diego, CA) with
paired-end 100 base pair reads. RNA-Seq reads were aligned
to the mouse reference genome (NCBI build 37.2) with
TopHat 2 (Trapnell et al 2009; Kim et al 2013); transcripts
were assembled and abundance was estimated with Cufflinks
(Trapnell et al 2010); differential expression was assessed
with CuffDiff (Trapnell et al 2013). Most conditions had three
animals per cohort, allowing for robust estimation of the sig-
nificance of expression changes with respect to animal-to-
animal variation (q-value <0.05).
Quantitative PCR
RNAwas extracted frommouse heart tissue using the RNeasy
Mini Kit and quantitative PCR carried out using TaqMan
Universal Master Mix II with UNG (Applied Biosystems)
on a 7900 HT Real-Time PCR Detection System (Applied
Biosystems) according to standard protocols, as previously
described (Wang et al 2013a). PCR primers were murine
Six1 (Mm00808212_ml, Life Technologies), murine Nmrk2
(Mm01172899_g1, Life Technologies), and endogenous con-
trol 18S (4333760, Life Technologies).
Gene set enrichment analysis
A functional analysis of differentially expressed genes was
performed using the DAVID database (Dennis et al 2003;
Huang et al 2009).
Text mining
We used the I2E indexing/semantic search tool (Linguamatics,
Cambridge, UK) for sentence identification, part of speech
tagging, and semantic analysis of sentences according to its
embedded linguistic rules (Hale 2005). Target genes and rela-
tional identification were correctly identified and parsed by
NLP algorithms within the I2E tool. Extracted relational data
was curated to disambiguate potential false positive hits (Chen
et al 2005).
Heart tissue metabolite profiling
Hearts that had been snap-frozen by immersion in liquid ni-
trogen immediately after dissection (maximum time of 5 mi-
nutes between sacrifice and freezing) were cut into pieces on
dry ice, homogenized (TissueLyser II, Qiagen), and extracted
with 80/20 MeOH/H2O (v/v) at a ratio of 150 μL extraction
solution to 5 mg tissue. Homogenized samples were centri-
fuged at 14,000 rpm for 15 min at 4°C. A volume of superna-
tant equivalent to 1 mg of tissue per well (30 μL) was trans-
ferred to 96-well plates and evaporated under reduced pres-
sure. Samples were analyzed using LC-MS. Prior to injection,
dried extracts were reconstituted (30 μL) in LC-MS-grade
water. Relative abundance of metabolites was evaluated by
high resolution accurate mass detection (HRAM). HRAM da-
ta was acquired using a Q Exactive™ Orbitrap mass spec-
trometer (Thermo Scientific) operated in both positive and
negative ion modes. LC-MS in positive mode was achieved
as previously described (Jha et al 2015). LC-MS in negative
ion mode was achieved using an Acquity UPLC® T3 C18
(3 μm, 2.0 × 150 mm) column (Waters Corporation, Milford,
MA) and by implementation of a gradient elution program as
previously described (Buescher et al 2010). Data were nor-
malized by weight.
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Statistical analysis
Statistical analyses were conducted using GraphPad Prism
(GraphPad Software Inc., La Jolla, CA).
Results
Idh2R140Q KI mice display a D2HGA type II phenotype
Constitutive expression of the Idh2R140Qmutant protein was
achieved by introducing the R140Q mutation into the native
Idh2 locus using a targeting vector, and systemic heterozy-
gous Idh2R140Q mutation confirmed by PCR genotyping
and sequencing (Supplementary Fig. 1a-c). Idh2 wild type
(Idh2wt) littermates served as controls for all analyses.
Idh2R140Q mice were viable and fertile, but obtained at a
slightly lower than expected Mendelian ratio (Supplementary
Fig. 2a), suggesting subtle prenatal abnormality. Substantially
higher mortality was observed in Idh2R140Q versus Idh2wt
mice (50 vs. 6.5 %) within 1 week of birth. Idh2R140Q mice
surviving after 1 week had lower body weight than Idh2wt
littermates during the first 5 weeks of life (Supplementary
Fig. 2b); this characteristic gradually disappeared after week
5.
Analysis of plasma, bone marrow, brain, spleen, and heart
demonstrated dramatically higher 2HG levels in Idh2R140Q
mice than Idh2wt littermates (Fig. 1a). Heart tissue displayed
the highest 2HG levels, correlating with observations of the
highest wild-type Idh2 mRNA and protein levels in heart tis-
sue. By week 14, mortality reached 50% in Idh2R140Qmice,
whereas all Idh2wt littermates survived (Fig. 1b); most deaths
were sudden. Periodic seizures occurred in 25 % of
Idh2R140Qmice and 10% displayed runting or abnormalities
of the face and head (Fig. 1c), consistent with clinical reports
of patients with D2HGA (Kranendijk et al 2012).
Idh2R140Q KI mice exhibit histopathological
abnormalities
Whole-body histopathology in Idh2R140Q mice identified
abnormalities of the cardiovascular, central nervous and uri-
nary systems. Compared with Idh2wt littermates, Idh2R140Q
mice had enlarged hearts, increased left ventricular mass/body
weight ratio (LVM/BW) and lower ejection fraction (EF)
(Supplementary Table 1), apparent as early as week 4.
Histopathology indicated increased ventricular wall thickness,
decreased luminal space, and hypertrophy of cardiomyocytes
characterized by cytoplasmic and nuclear enlargement
(Fig. 1d). On echocardiography, Idh2R140Q mice exhibited
severely decreased left ventricular wall motion and increased
dilation without a change in heart rate (Fig. 1e). These data
indicate cardiomyopathy, consistent with human D2HGA,
and may contribute to the shortened life span and sudden
deaths observed.
Developmental delay and seizures are observed in patients
with D2HGA (Kranendijk et al 2012). In Idh2R140Q mice,
vacuoles were consistently present in numerous brain struc-
tures (Fig. 1d), although their pathological significance in this
model is not yet clear (Supplementary material).
Severe hydronephrosis was evident, with massive dilation
of the renal pelvis and thinning of the renal cortex (Fig. 1d),
and increased kidney weight, blood urea nitrogen and creati-
nine values (Supplementary Table 1), suggesting functional
renal obstruction. This was surprising, as renal abnormalities
have not been described in patients with D2HGA.
Overall, the Idh2R140QKI mouse model recapitulates car-
diomyopathy and other disease features observed in patients
with D2HGA type II, thus providing a tool to further elucidate
the disease mechanism and evaluate treatment approaches.
Further analyses reported here focus mainly on cardiac
pathology.
AGI-026 inhibits 2HG production in IDH2R140Q mutant
cells
The triazine small molecule, AGI-026, is an orally bioavail-
able, selective, potent inhibitor of the human IDH2R140Q-
mutant enzyme (IC50 = 4.0 ± 0.2 nM [mean ± SD]; Fig. 2)
(International patent application WO2013102431A1). It did
not exhibit inhibition in a panel of dehydrogenases, including
lactate dehydrogenase and 3-phosphoglycerate dehydroge-
nases. The IC50 of 2HG production was similar in cultured
lymphoblasts from patients with D2HGA type II (5.4 ± 1.2
nM [mean ± SE]) and Idh2R140Q KI mouse embryonic stem
cells (5.4 ± 2.8 nM [mean ± SD]). AGI-026 displayed excel-
lent penetration of the blood-brain barrier inmice after a single
oral dose of 50 mg/kg (at 12 h post-dose, total brain to plasma
concentration ratio = 1.6 in Idh2wt and 1.9 in Idh2R140Q
mice).
AGI-026 rescues the 2DHGA type II phenotype
in Idh2R140Q mice
To assess the efficacy of AGI-026 in rescuing the pathophys-
iological defects in our mouse model, AGI-026 10 mg/kg or
vehicle was given by oral gavage twice daily (BID) for 13
weeks to Idh2R140Qmice, with dosing initiated at 4–5 weeks
of age. AGI-026 was well tolerated: body weight was main-
tained and mice were clinically indistinguishable from Idh2wt
controls. AGI-026 achieved 99 % reduction in 2HG in both
plasma and heart tissue (Fig. 3a). The survival rate was 100 %
in Idh2R140Q mice treated with AGI-026 (Idh2R140Q-AGI)
but only 46 % in Idh2R140Q mice receiving vehicle
(Idh2R140Q-veh) (Fig. 3b). Administration of a 50 mg/kg
dose did not provide additional 2HG reduction or survival
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benefit (data not shown). At study end, three females and three
males were randomly selected from each group for histopath-
ological examination. Compared with Idh2R140Q-veh mice,
Idh2R140Q-AGI mice had a lower incidence of myocardial
hypertrophy and sub-gross cardiomegaly (Fig. 3c;
Supplementary Table 2) and a lower average number of brain
sites affected by vacuolation (Supplementary Table 3).
Administration of AGI-026 had no effect on the incidence or
severity of hydronephrosis (data not shown).
Given that we observed 100 % survival and reduced inci-
dence of cardiac abnormalities at 10 mg/kg, we performed a
second study with a lower dose. Following administration of
AGI-026 at 2 mg/kg and 10 mg/kg BID continuously for 13
weeks, plasma 2HG was inhibited by 75 % and ∼100 %,
Fig. 1 Characteristics of
Idh2R140QKImice. (a) 2HG
levels in plasma (nmol/mL), bone
marrow, brain, spleen (all n = 4),
andheart (n = 7forIdh2wtandn = 5
for Idh2R140Q) in Idh2R140Qand
Idh2wtmice.Black horizontal bars
indicatemean. Statistical
significance (p) calculatedwith t
tests using theHolm-Sidakmethod
(p values shown above brackets).
(b)Kaplan-Meier survival curves in
Idh2R140Q and Idh2wtmice from
week 3. Statistical significance (p)
tested using the log-rank (Mantel-
Cox) test. (c)Abnormal phenotypes
(red arrow) in Idh2R140Qmice:
runting, facial dysmorphism, and
abnormal shape of the head. (d)
Histology of the heart, brain, and
kidney in Idh2R140Qmice at
approximately 12weeks of age
(hematoxylin and eosin stained).
Longitudinal sections of the whole
heart demonstrate ventricle wall
thickening, and cardiomyocytes
show hypertrophy. Transverse
sections of themid-brain showed
vacuoles were consistently present
in the lateral septal nuclei, various
strata of the CA1 andCA3 areas of
the hippocampus, the dentate gyrus,
and the anterior cingulate and
retrosplenial cortices, but were also
observed laterally and ventrally in
the cerebrum to involve themotor
(shown), somatosensory and
piriform cortices, particularly in the
deeper neuronal layers (3− 6), and
were also sometimes present in the
amygdala andmedulla. Transverse
sections of the whole kidney
illustrate hydronephrosis, showing
thinning of the cortex and almost
total loss of themedulla. Histology
is representative of sixmice per
group. (e) Echocardiographs
demonstrating cardiac functional
defects in 12-week old Idh2R140Q
mice
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respectively (Fig. 3d); the survival rate was 93 and 90 % in
Idh2R140Q-AGI mice receiving 2 mg/kg and 10 mg/kg, re-
spectively, and 67 % in Idh2R140Q-veh mice (Fig. 3e).
Echocardiography on all surviving mice at week 13 showed
significantly lower LVM/BW and significantly higher EF in
Idh2R140Q-AGI versus Idh2R140Q-veh mice (Fig. 3f, g), in-
dicating prevention of deterioration in cardiac function by
AGI-026. No differences were observed between the two
AGI-026 doses, indicating that doses achieving ≥75 % reduc-
tion of plasma 2HG are sufficient to prevent cardiac hypertro-
phy in this model.
Continuous administration of AGI-026 is required
to sustain benefit
To determine if continuous administration of AGI-026
was required to sustain benefit, and if Idh2R140Q inhi-
bition could reverse existing cardiac dysfunction, we
implemented treatment cross-over immediately after the
second 13-week efficacy study. Idh2R140Q-AGI mice
were switched to vehicle (Idh2R140Q-AGI/veh) and
Idh2R140Q-veh mice switched to AGI-026 10 mg/kg
(Idh2R140Q-veh/AGI) (Fig. 4a). Interim echocardiogra-
phy 1 month after cross-over showed a trend toward
improved cardiac function in Idh2R140Q-veh/AGI mice,
with decreases in LVM/BW and increases in EF (not
significant; Fig. 4b, c). All Idh2R140Q-AGI/veh mice
surviving at this interim time point showed a statistical-
ly significant increase in LVM/BW (p = 0.03; Fig. 4b)
and a decrease in EF (p = 0.007; Fig. 4c). After 8 weeks
of cross-over treatment, all seven Idh2R140Q-veh/AGI
mice survived versus only two of six Idh2R140Q-AGI/
veh mice. Thus, withdrawal of AGI-026 resulted in sig-
nificant deterioration in cardiac function, indicating that
continuous administration is necessary to sustain nor-
malization of cardiac function and provide survival
benefit.
DNA hydroxymethylation was decreased in heart tissue
of Idh2R140Q mice
2HG exerts epigenetic effects by competitive inhibition of
αKG-dependent dioxygenases, including histone
demethylases (Xu et al 2011; Lu et al 2012), and the ten-
eleven-translocation (Tet) enzymes (Xu et al 2011), which
mediate conversion of 5-methylcytosine (5mC) into 5-
hydroxymethylcytosine (5hmC) (Ito et al 2011). IDH-
mutated tumors display DNA hypermethylation, with signifi-
cantly lower 5hmC and higher 5mC levels versus IDHwt tu-
mors and normal tissues (Figueroa et al 2010; Liu et al 2012;
Turcan et al 2012; Wang et al 2013b; Kroeze et al 2014). As
there is currently no knowledge of DNA or histone methyla-
tion characteristics in D2HGA type II primary human sam-
ples, we assessed methylation patterns in heart tissue from
mutant versus wt mice. No differences were observed in his-
tone methylation at H3K9 and H3K27. However, %5hmC
was significantly lower in Idh2R140Q-veh than in Idh2wt-
veh mice (p = 0.006), and there was a non-significant trend
toward higher %5hmc in Idh2R140Q-AGI versus
Idh2R140Q-veh mice (Fig. 5a). Total 5mC was consistent in
all three groups (Fig. 5b).
Fig. 2 AGI-026, a brain-penetrant, potent and selective IDH2R140Q
mutant inhibitor. Structure and biochemical properties of AGI-026. IC50
for 2HG production was measured in vitro for IDH2R140Q homodimer
and IDH2wt/R140Q heterodimer recombinant purified enzymes. IC50 for
αKG production was measured in vitro for IDH2wt homodimer
recombinant purified enzyme. IC50 for 2HG production was measured
in: the engineered glioblastoma U87MG cell line overexpressing
IDH2R140Q or IDH1R132H; mouse Idh2R140Q embryonic stem
cells; lymphoblast cells obtained from three unrelated patients with
D2HGA type II. Mouse Idh2R140Q and human IDH2R140Q show
95.13 % identity
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Gene expression and metabolism are broadly
dysregulated in Idh2R140Q heart tissue
To test our hypothesis that the cardiomyopathy observed in
Idh2R140Q mice may be associated with systemic metabolic
dysregulation, we characterized genetic and metabolic alter-
ations in heart tissue using RNA sequencing and quantitative
metabolomics.
The genes and metabolites showing the greatest changes
represent a broad spectrum of metabolic pathways
Fig. 3 Efficacy of AGI-026 in
reversing thephenotypeobservedin
Idh2R140Qmice. Treatment was
administered twice daily for 13
weeks. (a) Inhibition of 2HG in
plasma and heart following 6
weeks’ treatment withAGI-026 10
mg/kgcomparedwithvehicle(n = 8
for plasma, n = 7 for heart Idh2wt-
veh, and n = 5 for other groups). (b)
Kaplan-Meier survival curves in
Idh2R140Qmice treatedwith 10
mg/kgAGI-026 or vehicle and
Idh2wtmice receiving vehicle.
Statistical significance (p) tested
using the log-rank (Mantel-Cox)
test. (c) Histopathological analysis
of heart tissue in Idh2wtmice and
Idh2R140Qmicewith andwithout
AGI-026 treatment, showing rescue
of cardiac hypertrophy
(cytoplasmic and nuclear
enlargement) with treatment (scale
bar denotes 100μm). (d) Inhibition
of 2HG in plasma following 6
weeks’ treatmentwithAGI-026
comparedwithvehicle in thesecond
efficacy study (n = 20 for Idh2wt-
veh, n = 21 for Idh2R140Q-veh,
n = 14 for Idh2R140Q-AGI 2mg/
kg, andn = 10 for Idh2R140Q-AGI
10mg/kg);% inhibition calculated
as 100% in Idh2wt-veh and 0% in
Idh2R140Q-veh. (e) Kaplan-Meier
survival curves in Idh2R140Qmice
treatedwith 2mg/kgAGI-026, 10
mg/kgAGI-026 or vehicle and
Idh2wtmice receiving vehicle.
Statistical significance (p) tested
using the log-rank (Mantel-Cox)
test. (f) Left ventricular mass/body
weight ratioand(g)ejection fraction
assessed by echocardiogram at
week 13 (n = 20 for Idh2wt-veh,
n = 16 for Idh2R140Q-veh, n= 13
for Idh2R140Q-AGI 2mg/kg, and
n = 9 for Idh2R140Q-AGI 10mg/
kg). Error bars represent mean ±
standard deviation; statistical
significance (p) was testedwith
one-wayANOVAwith Sidak’s
multiple comparison test
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(Supplementary Table 4), indicating widespread metabolic
perturbation in the Idh2R140Q mouse heart. Significant dif-
ferences (p < 0.05) in the expression of 174 genes were
observed in Idh2R140Q versus Idh2wt heart tissue.
Functional annotation revealed significant enrichment in ami-
no acid metabolism and cofactors of cellular functions such as
differentiation, cell signaling, antigen processing, and muscle
morphology and development (Supplementary Table 5).
Three genes contributing to the antigen processing enrichment
(GO category 0019886) were upregulated by ∼2-fold in
Idh2R140Q mouse hearts (histocompatibility receptors,
Entrezgene IDs: 14960, 14961 and 14969). Using natural lan-
guage processing-based text mining (Friedman et al 2001;
Novichkova et al 2003; Jensen et al 2006) in MEDLINE, we
sought published causal associations between the differential-
ly expressed genes and cardiomyopathy, cardiomyocyte de-
velopment and differentiation or dysregulated metabolism,
and identified 52 candidates showing at least a twofold change
(21 upregulated, 31 downregulated; p < 0.05; Fig. 6a).
Processes regulated by these genes include cardiac muscle
growth and differentiation, muscle structure, regulation of
contraction, and regulation of muscle cell metabolism
(Supplementary Table 4). Several have been shown to be ad-
versely associated with heart failure, namely the transcription
factors HOP homeobox (Hopx) (Trivedi et al 2011) and Six
homeobox 1 (Six1) (Delgado-Olguin et al 2012; Wu et al
2014), the cytoskeletal regulator tropomodulin 4 (Tmod4)
(Zhao et al 2013), and the metabolic gene nicotinamide
riboside kinase 2 (Nmrk2) (Ruggieri et al 2015). In
Idh2R140Q mouse hearts we observed a twofold downregu-
lation in Hopx expression, a 25-fold downregulation in
Tmod4, a 25-fold upregulation in Nmrk2, and an 11-fold up-
regulation in Six1, as well as upregulation of Six1 downstream
targets (Fig. 6a, b; Supplementary Table 6). AGI-026 treat-
ment reversed the majority of these Idh2R140Q-induced
changes, with expression of 18 of the 21 upregulated and 23
of the 31 downregulated genes being normalized to levels
seen in Idh2wt mice, including Hopx, Tmod4 and Nmrk2
(p = 0.049) (Fig. 6a, b). AGI-026 treatment failed to reduce
Six1 expression (Fig. 6a, b).
Significant Idh2R140Q-induced differences in levels were
observed for 56 of 126 metabolites assessed in heart tissue
(p < 0.05, Supplementary Table 7). The magnitude of change
ranged from 1.2- to 25-fold, with 48 increasing (excluding
2HG) and seven decreasing (Fig. 6c). Notably, in
Idh2R140Q-veh compared to Idh2wt-veh hearts we observed
decreases in tricarboxylic acid cycle (TCA) intermediates glu-
tamate (43 % reduction; p = 0.01), malate (62 % reduction;
p = 0.03), and aspartate (59 % reduction; p = 0.01), as well
as elevations in intermediates of glycogenolysis and glycoly-
sis (Fig. 6d), and a twofold increase in the second messenger,
cAMP, all of which were normalized with AGI-026 treatment
(Fig. 6c, d). Consistent with increased cAMP, we observed a
significant increase in expression of its downstream target,
phosphodiesterase 3B (Maurice et al 2003) (Pde3b; Fig. 6a).
AGI-026 treatment reversed dysregulation in the majority of
Fig. 4 Cross-over study to determine effects of withdrawal of AGI-026
treatment. (a) Cross-over study design. (b) Left ventricular mass/body
weight and (c) ejection fraction before and after cross-over study
treatment (n = 9 in Idh2wt, n = 7 in Idh2R140Q-veh/AGI, and n = 4 in
Idh2R140Q-AGI/veh). Error bars represent mean ± standard deviation.
Statistical significance (p) tested with one-way ANOVA with Sidak’s
multiple comparison test
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these significantly altered metabolites in the Idh2R140Q
mouse heart (Fig. 6c, d; Supplementary Table 7). Plotting
the fold-change for Idh2R140Q-AGI/Idh2R140Q-veh treated
mice against fold-change for Idh2R140Q-veh/Idh2wt-veh
treated mice yielded a slope of −0.89 and a coefficient of
determination of 0.90 (Fig. 6e).
Taken together, these data indicate differential expression
of multiple genes and metabolites associated with cardiomy-
opathy in Idh2R140Q mice, which were largely reversed by
AGI-026.
Discussion
We have generated a novel mouse model of D2HGA type II, a
rare neurometabolic disorder caused by germline gain-of-
function mutations in IDH2. Our Idh2R140Q KI model dis-
plays dramatically elevated 2HG levels in plasma, bone mar-
row, heart, spleen, and brain compared with Idh2wt litter-
mates, which is associated with early onset cardiomyopathy,
brain abnormalities, shortened life span, and in some mice,
periodic seizures, runting, and face/head abnormalities. We
demonstrated that treatment with AGI-026, a selective,
brain-penetrant IDH2R140Q inhibitor, not only prevented
progression of cardiomyopathy in young Idh2R140Q mice
but also ameliorated cardiomyopathy in adult animals, and
provided a survival benefit in this model, with continuous
administration being required to sustain these benefits. We
also observed differential expression of multiple genes and
metabolites in Idh2R140Q hearts, some of which have been
associated with cardiomyopathy, that were largely reversed by
AGI-026 treatment. Our findings provide proof-of-concept for
the clinical potential of mutant IDH2 inhibition in treating this
neurometabolic disorder.
The association of a more severe D2HGA phenotype with
the higher 2HG levels observed in type II versus type I disease
points to a key role for 2HG in disease pathogenesis.
Cardiomyopathy occurs in ∼50 % type II cases but not in type
I, and our data show that a 75 % reduction in plasma 2HG is
sufficient to ameliorate cardiomyopathy in this mouse model,
suggesting that only very high 2HG levels induce this pathol-
ogy. Notably, wild-type Idh2 mRNA and protein expression is
highest in heart tissue. However, cardiomyopathy in D2HGA
type II may also be related to NADPH deficiency resulting
from consumption of this co-factor in the reduction ofαKG to
2HG by mutant IDH2. Alterations in NADP+/NADPH ratios
affect intermediary metabolism that may have subsequent ef-
fects on cardiac function (Ussher et al 2012). In the heart,
NADPH plays a role in fatty acid synthesis and also regulation
of oxidative stress through the thioredoxin system, which uti-
lizes NADPH to regulate the redox status of various intracel-
lular proteins, resulting in a cardioprotective effect (Ussher
et al 2012).
Fig. 6 Differences in metabolite levels and gene expression in
Idh2R140Q and Idh2wt heart tissue and effect of AGI-026. For heat
maps (a) and (c), red indicates an increase, blue a decrease, darker
colors indicate greater change, and pale colors indicate less change. Left
column shows difference for Idh2R140Q versus Idh2wt, central column
shows difference for AGI-026 versus vehicle treatment in Idh2R140Q
mice, and right column shows difference for AGI-026-treated
Idh2R140Q versus Idh2wt mice (pale colors illustrate correction of
alterations by AGI-026 and shift to Idh2wt status). (a) Expression
changes in 52 candidate genes with ≥ 2-fold difference between
Idh2R140Q (n = 6) and Idh2wt (n = 5); (Idh2R140Q-AGI n = 6). (b)
Quantitative RT-PCR validation of expression changes in two candidate
genes, shown as relative expression normalized to one Idh2wt sample.
Each data point represents the mean of a technical triplicate from each of
the five animals per group. P tested using Kruskal-Wallis tests with
Dunn’s multiple comparison test. For all figures horizontal black bars
indicate group means. (c) The metabolites (excluding 2HG) that were
significantly changed (p < 0.05) in heart tissue of Idh2R140Q versus
Idh2wt mice, and effects of AGI-026. (d) Levels of cAMP and metabo-
lites in the glycogenolysis and glycolysis pathways that are corrected by
AGI-026 treatment. Statistical significance (p) was tested with one-way
ANOVA with Sidak’s multiple comparison test (n = 10 Idh2wt-veh and
Idh2R140Q-AGI, n = 5 Idh2R140Q-veh). (e) Correlation of fold-changes
for Idh2R140Q-AGI versus Idh2R140Q-veh against Idh2R140Q-veh
versus Idh2wt-veh for the metabolites in heart tissue significantly altered
by Idh2R140Q expression (excluding 2HG). Red dots indicate metabo-
lites significantly changed on both axes (n = 32). R2 denotes coefficient of
determination
Fig. 5 5hmC and 5mC levels in heart tissue of mice. Percentage of 5hmc
(a) or 5mc (b) in hearts of Idh2wt mice receiving vehicle (n = 10) and
Idh2R140Qmice treated for 13weeks with vehicle (n = 5) or AGI-026 10
mg/kg (n = 10). Error bars represent mean ± standard deviation. Statistical
significance (p) was tested by one-way ANOVA with Sidak’s multiple
comparison test
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Given that 2HG inhibits histone and DNA demethylases
(Figueroa et al 2010; Chowdhury et al 2011; Xu et al 2011),
changes in 5hmC/5mC are expected.We observed significant-
ly lower %5hmC in heart tissue of Idh2R140Q mice, which
was increased by AGI-026 treatment, although this did not
reach significance in the mouse model, possibly as a result
of a less severe phenotype in surviving Idh2R140Q mice.
No difference in 5mc levels was observed. Others have shown
changes in 5hmC without concomitant 5mC changes in
IDH1/2-mutant tissues or cells (Kraus et al 2012; Chen et al
2013), and in spleens of mice engrafted with IDH2R140Q-
transduced progenitor cells (Mylonas et al 2014). As the
5mC pool is much larger than the 5hmC pool, it is possible
that the technique used was not sensitive enough to detect
relatively subtle changes in 5mC. Our data suggest that aber-
rant DNA hydroxymethylation may play a role in cardiomy-
opathy in this model, consistent with other reports indicating
epigenetic changes in human heart failure (Movassagh et al
2011) and the role of epigenetics in cardiac development and
homeostasis (Delgado-Olguin et al 2012). Accordingly, we
identified differential expression in several genes in
Idh2R140Q mouse hearts that, when dysregulated, could be
implicated in cardiomyopathy, including downregulation of
Hopx (Trivedi et al 2011) and Tmod4 (Zhao et al 2013) and
upregulation of Six1 (Delgado-Olguin et al 2012; Wu et al
2014) and Nmrk2 (Li et al 1999; Ruggieri et al 2015).
Assessment of AGI-026-mediated transcriptional changes in
fibroblasts from a patient with D2HGA type II also revealed
gene pathways with known relevance in cardiovascular sys-
tem development and function (including cardiac hypertro-
phy), and myogenesis (personal communication, MDD and
Stéphane de Botton). Cardiomyopathy has been linked to de-
fects in myocardial energy production (Ingwall 2009), in-
creased oxidative stress (Christiansen et al 2015), and struc-
tural defects in cardiomyocytes (Harvey and Leinwand 2011).
Fatty acids are the primary source of energy in the healthy
heart (Strauss and Johnson 1996), but in heart failure there is
a shift toward glycolysis (Allard et al 1994). Metabolite pro-
filing of Idh2R140Q mouse heart tissue reflected these obser-
vations, with significant increases in levels of glycolytic inter-
mediates and decreases in steady-state levels of the TCA and
anaplerotic metabolites, glutamate, malate and aspartate, con-
sistent with observations in human cancer cells expressing
IDH1/2 mutations (Reitman et al 2011). Given that these al-
terations are observed across different tissues, they likely rep-
resent a shared metabolic burden of IDH mutation, although it
is not yet clear whether they are the cause or consequence of
cardiomyopathy.We also observed increases in cAMP; chron-
ic activation of the cAMP/protein kinase A pathway stimu-
lates glycogen breakdown and glycolysis in the heart and is
believed to contribute to the pathophysiology of cardiomyop-
athy (Depre et al 1998; Movsesian 2004). Together, our data
show that the Idh2R140Q mutation induces significant
epigenetic, transcriptional, and metabolic dysregulation in
heart tissue. Our metabolic profiling may be limited by the
speed at which we were able to freeze the tissues. Intervals
of <5 seconds between life and freezing are the ideal for cap-
turing metabolite status due to significant changes occurring
rapidly upon induction of anoxia (Faupel et al 1972; Hearse
1983). Although there is a risk our metabolic profiling was not
exhaustive, the results are nevertheless informative as they
reflect significant differences between Idh2R140Q mutant,
AGI-026 treated, and matching control Idh2wt mice from
the same experimental setting, and they are also supported
by the expression profiling data.
Patients with D2HGA type II have a limited life span and
exhibit a wide spectrum of symptoms including developmen-
tal delay, epilepsy, and cardiomyopathy in ∼50 % of cases.
Our Idh2R140Q mouse model recapitulates these defects and
thus provides a valuable preclinical system to further charac-
terize D2HGA type II and to evaluate approaches for thera-
peutic intervention. A previously reported transgenic mouse
model over-expressing Idh2R140Q or Idh2R172K mutations
under post-natal, conditional activation displayed elevated se-
rum 2HG, cardiomyopathy, brain vacuoles and muscular dys-
trophy, with a more severe phenotype when Idh2R140Q was
embryonically activated (including runting, tremors, seizures,
hydrocephalus, and shortened lifespan). Improvements in car-
diac function and survival were observed on elimination of
transgene expression (Akbay et al 2014). This study also not-
ed the same upregulation of gene expression in the antigen
processing and presentation category (GO:0019886) that we
observed, potentially indicating a connection between
Idh2R140Q expression and specific immune responses. The
renal abnormalities observed in our model were not described
in the transgenic mouse model (Akbay et al 2014), and were
not rescued by AGI-026, suggesting that they may be mouse-
strain specific. Our metabolic findings were generally consis-
tent with the Idh2R140Q transgenic mouse model (Akbay
et al 2014), although there appear to be some differences re-
garding glycogen and glucose metabolism. However, in the
transgenic model, high levels of mutant Idh2 from a non-
native promoter were expressed upon tamoxifen administra-
tion from 5 weeks of age, whereas our approach introduced
the Idh2R140Q mutation at the endogenous chromosomal lo-
cus, resulting in physiological regulation of expression begin-
ning in embryogenesis. Consequently, our model reflects the
genetic, developmental, and physiological circumstances of
the disease in humans. The suitability of our model for early
administration of experimental small molecule inhibitors also
carries implications for future clinical intervention and
prevention.
The observations that the IDH2R140Q inhibitor, AGI-026,
rescued cardiomyopathy and provided a survival benefit in
this model through 2HG reduction, and potently inhibited
2HG production in lymphoblasts from D2HGA patients
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carrying IDH2R140Q mutations, suggest that mutant IDH2
inhibition has therapeutic potential in D2HGA type II.
Importantly, administration of AGI-026 largely reversed the
transcriptional and metabolic alterations in heart tissue, pro-
viding insight into the pathophysiology of cardiomyopathy in
D2HGA type II. Further investigation is warranted to deter-
mine the molecular mechanisms behind these changes.
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